|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0023449,
umls-concept:C0087111,
umls-concept:C0205217,
umls-concept:C0205263,
umls-concept:C0205653,
umls-concept:C0220901,
umls-concept:C0237881,
umls-concept:C0439834,
umls-concept:C0449450,
umls-concept:C0684224,
umls-concept:C0750502,
umls-concept:C0871261,
umls-concept:C1456649,
umls-concept:C1516476,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2348519,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1997-7-21
|
|
pubmed:abstractText |
Compared with previous Children's Cancer Group (CCG) acute lymphoblastic leukemia (ALL) trials, therapy based on the Berlin-Frankfurt-Munster (BFM) 76 trial has effected an improvement in event-free survival (EFS). In an attempt to improve EFS further, CCG investigators formulated an augmented BFM (A-BFM) regimen that provides prolonged, intensified postinduction chemotherapy relative to the CCG-modified BFM regimen.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2222-30
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9196134-Adolescent,
pubmed-meshheading:9196134-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9196134-Asparaginase,
pubmed-meshheading:9196134-Child,
pubmed-meshheading:9196134-Child, Preschool,
pubmed-meshheading:9196134-Daunorubicin,
pubmed-meshheading:9196134-Disease-Free Survival,
pubmed-meshheading:9196134-Humans,
pubmed-meshheading:9196134-Infant,
pubmed-meshheading:9196134-Life Tables,
pubmed-meshheading:9196134-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:9196134-Prednisone,
pubmed-meshheading:9196134-Prognosis,
pubmed-meshheading:9196134-Time Factors,
pubmed-meshheading:9196134-Treatment Outcome,
pubmed-meshheading:9196134-Vincristine
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
|
|
pubmed:affiliation |
University of Chicago, IL, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study
|
